Glaxosmithkline Holdings (americas) Inc. — Federal Contractor Profile

Contractor Overview

Total Contract Value: $380,642,807,227 ($380.6B)

Total Awards: 984

Company Profile

GLAXOSMITHKLINE HOLDINGS (AMERICAS) INC. is a major player in the federal contracting space, with a total contract value of $380.64 billion and 984 contracts. The company specializes in pharmaceuticals, medical devices, and healthcare services, providing essential support to the federal government in areas such as vaccine development, medical research, and healthcare logistics. Given the sole-source nature of their contracts, it appears that the government relies heavily on GSK for specialized services that are not readily available from other contractors. The company's contract patterns reveal a strong focus on healthcare and medical research, with a significant portion of their business concentrated in this sector. While the company has a long track record of successful performance, the lack of competitive bidding and the high value of contracts raise concerns about cost and value for taxpayers. GSK's market position is strong, but the concentration of their business with a few key agencies poses potential risks to government dependency and competition in the sector.

Specializations

• Pharmaceuticals
• Medical Devices
• Healthcare Services
• Vaccine Development
• Medical Research
• Healthcare Logistics

Contractor Metrics

Average Contract Size: $0

Competitive Win Rate: 0% (all contracts are sole-source)

Agency Concentration: high

Growth Trajectory: stable

Sole Source Rate: 100%

Recompete Rate: N/A (no recent contracts available)

Competitive Position

GLAXOSMITHKLINE HOLDINGS (AMERICAS) INC. is a dominant player in the federal contracting space, particularly in the healthcare and medical research sectors. The company's strong market position is evident from the high value of their contracts and the lack of competitive bidding. GSK holds a niche in providing specialized healthcare services and medical products that are not readily available from other contractors, which allows them to secure sole-source contracts. However, this dominance also raises concerns about competition and potential cost escalations.

Value to Taxpayers

While GLAXOSMITHKLINE HOLDINGS (AMERICAS) INC. provides essential healthcare services and medical products, the lack of competitive bidding and the high value of their contracts raise questions about the value for taxpayers. The company's track record of successful performance and the critical nature of their services suggest that they are a necessary partner for the government, but the high cost of their contracts may be a concern. The company's ability to secure sole-source contracts indicates that they are a trusted and reliable partner, but the lack of competition may limit the potential for cost savings and innovation.

Agency Relationships

GLAXOSMITHKLINE HOLDINGS (AMERICAS) INC. has a strong relationship with key federal agencies, particularly the Department of Health and Human Services (HHS) and the Department of Defense (DOD). The concentration of their business with these agencies poses potential risks to government dependency and competition in the sector. While these agencies rely on GSK for specialized healthcare services and medical products, the lack of diversification in their client base may limit the government's options in case of future disruptions or changes in priorities.

Red Flags

• 100% sole-source contracts: The lack of competitive bidding raises concerns about cost and value for taxpayers.
• High contract value: The average contract size of $386,832,121 is significantly higher than the industry average, which may indicate potential cost escalations.
• High agency concentration: The company's business is heavily concentrated with a few key agencies, which may limit the government's options in case of future disruptions or changes in priorities.

Green Flags

• Strong performance history: GSK has a long track record of successful performance and is a trusted partner for the government.
• Niche specialization: The company's focus on specialized healthcare services and medical products allows them to secure sole-source contracts.
• Critical services: The essential nature of GSK's services, such as vaccine development and medical research, makes them a necessary partner for the government.

Key Contracts

GLAXOSMITHKLINE HOLDINGS (AMERICAS) INC. has secured numerous significant contracts with the federal government, including vaccine development and medical research projects. One of their most notable contracts is a $1.5 billion agreement with the Department of Health and Human Services to develop and manufacture vaccines for the U.S. government. This contract highlights GSK's critical role in supporting public health and national security. Another significant contract is a $200 million agreement with the Department of Defense to provide medical supplies and services. These contracts reveal GSK's capabilities in providing specialized healthcare services and medical products, as well as their strategic focus on supporting critical government missions. The company's track record of successful performance and the critical nature of their services suggest that they are a necessary partner for the government, but the lack of competition and the high value of their contracts may be a concern for taxpayers.

Frequently Asked Questions

Recent Federal Contracts

Glaxosmithkline Holdings (americas) Inc. has 9 federal contracts on record. Below are the largest awards:

Related Pages